Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis

Cancer Causes and Control

Volumn 28, Issue 6, 2017, Pages 497-528

  Harrison, Sean ^a   Lennon, Rosie ^a   Holly, Jeff ^b   Higgins, Julian P T ^a   Gardner, Mike ^a,c   Perks, Claire ^b   Gaunt, Tom ^a   Tan, Vanessa ^a   Borwick, Cath ^a,d   Emmet, Pauline ^a   Jeffreys, Mona ^a   Northstone, Kate ^a   Rinaldi, Sabina ^e   Thomas, Stephen ^a   Turner, Suzanne D ^f   Pease, Anna ^a   Vilenchick, Vicky ^a   Martin, Richard M ^a,g   Lewis, Sarah J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Insulin like growth factors; Mechanistic pathway; Meta analysis; Milk; Prostate cancer; Systematic review

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 2;

CANCER GROWTH; CANCER RISK; DISEASE ASSOCIATION; EFFECT SIZE; EXPERIMENTAL STUDY; FOOD INTAKE; HUMAN; MILK; NONHUMAN; OBSERVATIONAL STUDY; PHENOTYPE; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TUMOR GROWTH; TUMOR VOLUME; ADVERSE EFFECTS; ANIMAL; DISEASE COURSE; MALE; META ANALYSIS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RISK;

ANIMALS; DISEASE PROGRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MILK; PROSTATE; PROSTATIC NEOPLASMS; RISK;

EID: 85016470744     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-017-0883-1     Document Type: Review

References (199)

1. World Cancer Research Fund International/American Institute for Cancer Research Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer, available at: [http://www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf]
2. Tate PL, Bibb R, Larcom LL (2011) Milk stimulates growth of prostate cancer cells in culture. Nutr Cancer 63(8):1361–1366
3. Gilbert R, Martin RM, Beynon R et al (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22(3):319–340
4. Sumpter JP (1998) Xenoendocrine disrupters - environmental impacts. Toxicol Lett 103:337–342
5. Qin LQ, Wang PY, Kaneko T et al (2004) Estrogen: one of the risk factors in milk for prostate cancer. Med Hypotheses 62(1):133–142
6. Qin LQ, He K, Xu JY (2009) Milk consumption and circulating insulin-like growth factor-I level: a systematic literature review. Int J Food Sci Nutr 60:330–340
7. Rowlands MA, Gunnell D, Harris R et al (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429
8. Rowlands MA, Holly JMP, Gunnell D et al (2012) Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: The Large Case-Control Study ProtecT. Cancer Res 72(2):503–515
9. Roddam AW, Allen NE, Appleby P et al (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(7):461–488
10. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
11. Harrison S, Jones H, Martin RM et al (2017) The Albatross plot: a novel graphical tool for presenting results of diversely reported studies in a systematic review. Res Synth Methods (in press)
12. Stouffer SA, Suchman EA, DeVinney LC et al (1949) The American soldier, vol. 1, Adjustment during army life. J Consult Psychol 13(4):310–310
13. Chene G, Thompson SG (1996) Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 144(6):610–621
14. Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to metaanalysis. Am J Epidemiol 135(11):1301–1309
15. Orsini N, Bellocco R, Greenland S (2006) Generalized least squares for trend estimation of summarized dose-response data. Stata J 6(1):40–57
16. Harris RJ, Bradburn MJ, Deeks JJ et al (2008) Metan: fixed- and random-effects meta-analysis. Stata J 8(1):3–28
17. Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558
18. Egger M, Smith GD, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315(7109):629–634
19. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101
20. Altman DG, Bland JM (2003) Statistics Notes - Interaction revisited: the difference between two estimates. Br Med J 326(7382):219–219
21. Sterne JAC, Hernan MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ-Br Med J 355:i4919
22. CASP Case Control Checklist [http://media.wix.com/ugd/dded87_63fb65dd4e0548e2bfd0a982295f839e.pdf]
23. CASP Cohort Study Checklist [http://media.wix.com/ugd/dded87_e37a4ab637fe46a0869f9f977dacf134.pdf]
24. Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 336(7650):924–926
25. Schaefer C, Friedman GD, Quesenberry Jr (1998) CP: IGF-1 and prostate cancer. Science 282:199
26. Safarinejad MR, Shafiei N, Safarinejad S (2011) Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3. Growth Horm IGF Res 21(3):146–154
27. Martin RM, Holly JMP, Middleton N et al (2007) Childhood diet and insulin-like growth factors in adulthood: 65-year follow-up of the Boyd Orr Cohort. Eur J Clin Nutr 61(11):1281–1292
28. Ben-Shlomo Y, Holly J, McCarthy A et al (2005) Prenatal and postnatal milk supplementation and adult insulin-like growth factor I: long-term follow-up of a randomized controlled trial. Cancer Epidemiol Biomark Prev 14(5):1336–1339
29. Colangelo LA, Chin BCH, Liu K et al (2005) IGF-1, IGFBP-3, and nutritional factors in young black and white men: the CARDIA Male Hormone Study. Nutr Cancer 53(1):57–64
30. Rich-Edwards JW, Ganmaa D, Pollak MN et al (2007) Milk consumption and the prepubertal somatotropic axis. Nutr J 6:28
31. McGreevy KM, D Hoel B, Lipsitz SR et al (2007) Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males. Public Health Nutr 10(1):97–105
32. Esterle L, Sabatier JP, Guillon-Metz F et al (2009) Milk, rather than other foods, is associated with vertebral bone mass and circulating IGF-1 in female adolescents. Osteoporos Int 20(4):567–575
33. Thorisdottir B, Gunnarsdottir I, Palsson GI et al (2013) Protein sources in infancy as predictors for body mass index and IGF-1 concentration at the age of 6 years. Ann Nutr Metab 63:793–793
34. Tsilidis KK, Travis RC, Appleby PN et al (2013) Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Int J Cancer 133(2):495–504
35. Mucci LA, Tamimi R, Lagiou P et al (2001) Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? Bju Int 87(9):814–820
36. Ma J, Giovannucci E, Pollak M et al (2001) Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. J Natl Cancer Inst 93(17):1330–1336
37. Holmes MD, Pollak MN, Willett WC et al (2002) Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomark Prev 11(9):852–861
38. Giovannucci E, Pollak M, Liu Y et al (2003) Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomark Prev 12(2):84–89
39. Gunnell D, Oliver SE, Peters TJ et al (2003) Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 88(11):1682–1686
40. DeLellis K, Rinaldi S, Kaaks RJ et al (2004) Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomark Prev 13(9):1444–1451
41. Hoppe C, Udam TR, Lauritzen L et al (2004) Animal protein intake, serum insulin-like growth factor I, and growth in healthy 2.5-year-old Danish children. Am J Clin Nutr 80(2):447–452
42. Morimoto LM, Newcomb PA, White E et al (2005) Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: Personal and lifestyle factors (United states). Cancer Causes Control 16(8):917–927
43. Rogers I, Emmett P, Gunnell D et al (2006) Milk as a food for growth? The insulin-like growth factors link. Public Health Nutr 9(3):359–368
44. Norat T, Dossus L, Rinaldi S et al (2007) Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Eur J Clin Nutr 61(1):91–98
45. Budek AZ, Hoppe C, Michaelsen KE et al (2007) Associations of total, dairy, and meat protein with markers for bone turnover in healthy, prepubertal boys. J Nutr 137(4):930–934
46. Crowe FL, Key TJ, Allen NE et al (2009) The Association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev 18(5):1333–1340
47. Maruyama K, Iso H, Ito Y et al (2009) Associations of food and nutrient intakes with serum IGF-I, IGF-II, IGFBP-3, TGF-beta 1, Total SOD activity and sFas levels among middle-aged Japanese: the JACC Study. Asian Pac J Cancer Prev 10:6–22
48. Young NJ, Metcalfe C, Gunnell D et al (2012) A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. Cancer Causes Control 23(6):907–917
49. Delellis Henderson K, Rinaldi S, Kaaks R et al (2007) Lifestyle and dietary correlates of plasma insulin-like growth factor binding protein-1 (IGFBP-1), leptin, and C-peptide: the multiethnic cohort. Nutr Cancer 58(2):136–145
50. Cadogan J, Eastell R, Jones N et al (1997) Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. BMJ 315(7118):1255–1260
51. Heaney RP, McCarron DA, Dawson-Hughes B et al (1999) Dietary changes favorably affect bone remodeling in older adults. J Am Diet Assoc 99(10):1228–1233
52. Zhu K, Du XQ, Cowell CT et al (2005) Effects of school milk intervention on cortical bone accretion and indicators relevant to bone metabolism in Chinese girls aged 10–12 years in Beijing. Am J Clin Nutr 81(5):1168–1175
53. Hoppe C, Molgaard C, Juul A et al (2004) High intakes of skimmed milk, but not meat, increase serum IGF-I and IGFBP-3 in eight-year-old boys. Eur J Clin Nutr 58(9):1211–1216
54. Hrolfsdottir L, Rytter D, Bech BH et al (2013) Maternal milk consumption, birth size and adult height of offspring: a prospective cohort study with 20 years of follow-up. Eur J Clin Nutr 67(10):1036–1041
55. Joslowski G, Remer T, Assmann KE et al (2013) Animal protein intakes during early life and adolescence differ in their relation to the growth hormone-insulin-like-growth-factor axis in young adulthood. J Nutr 143(7):1147–1154
56. Signorello LB, Kuper H, Lagiou P et al (2000) Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur J Cancer Prev 9(3):173–178
57. Larsson SC, Wolk K, Brismar K et al (2005) Association of diet with serum insulin-like growth factor I in middle-aged and elderly men. Am J Clin Nutr 81(5):1163–1167
58. Ambrosini-Spaltro A, Farnedi A, Montironi R et al (2011) IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma. Appl Immunohistochem Mol Morphol 19(4):318–328
59. Belharazem D, Kirchner M, Geissler F et al (2012) Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer. Endocr Connect 1(2):87–94
60. Bhusari S, Yang B, Kueck J et al (2011) Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate 71(15):1621–1630
61. Cardillo MR, Monti S, Di Silverio F et al: Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003, 23(5A):3825–3835
62. Chang CF, Pao JB, Yu CC et al (2013) Common variants in IGF1 pathway genes and clinical outcomes after radical prostatectomy. Ann Surg Oncol 20(7):2446–2452
63. Figueroa JA, De Raad S, Tadlock L et al (1998) Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 159(4):1379–1383
64. Hampel OZ, Kattan MW, Yang G et al (1998) Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol 159(6):2220–2225
65. Hetzl AC, Favaro WJ, Billis A et al (2012) Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men. Microsc Res Tech 75(9):1197–1205
66. Hu CK, McCall S, Madden J et al (2006) Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. Prostate Cancer Prostatic Dis 9(1):62–67
67. Ito K, Yamamoto T, Miyakubo M et al (2009) Impact of insulin-like growth factor (igf) kinetics on the development of prostate cancer: age-adjusted and baseline Psa-adjusted case control study. J Urol 181(4):658–658
68. Johansson M, Mckay JD, Stattin P et al (2007) Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. Int J Cancer 120(3):539–542
69. Lai MT, Chen RH, Tsai FJ et al (2005) Glutathione S-transferase M1 gene but not insulin-like growth factor-2 gene or epidermal growth factor gene is associated with prostate cancer. Urol Oncol 23(4):225–229
70. Latif Z, McMillan DC, Wallace AM et al (2002) The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int 89(4):396–399
71. Linos KD, Lu S, Ross JS et al (2009) Insulin-Like growth factor binding protein 3 (IGFBP-3) is up-regulated in prostatic adenocarcinoma (PAC) and correlates with gleason grade. Lab Invest 89:179A–179A
72. Liu ZW, Zhou FJ, Luo YM et al (2006) [Genomic imprinting of insulin-like growth factor II in prostate cancer and its clinical significance]. Ai Zheng 25(6):765–770
73. Massoner P, Rennau ML, Heidegger I et al (2011) Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-beta treatment. Am J Pathol 179(6):2905–2919
74. Mita K, Nakahara M, Usui T (2000) Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients. Int J Urol 7(9):321–329
75. Mucci LA, Stark JR, Pollak MN et al (2010) Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: A Prospective Study. Cancer Epidemiol Biomark Prev 19(2):484–491
76. Okugi H, Koike H, Sekine Y et al (2006) Methylation status of insulin-like growth factor-binding protein-3 promoter in prostate cancer tissues. Asia–Pac J Clin Oncol 2:144–149
77. Oliver SE, Jefferson K, Gunnell D et al (2003) IGF-axis and screen-detected prostate cancer: a cross-sectional study. J Urol 169(4):161–161
78. Paradowska A, Fenic I, Konrad L et al (2009) Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia. Int J Oncol 35(1):87–96
79. Perry AS, Loftus B, Moroose R et al (2007) In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer. Br J Cancer 96(10):1587–1594
80. Richardsen E, Ukkonen T, Bjornsen T et al (2003) Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Arch 442(4):329–335
81. Rowlands MA, Holly JMP, Hamdy F et al (2012) Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control 23(2):347–354
82. Ryan CJ, Haqq CM, Simko J et al (2007) Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 25(2):134–140
83. Savvani A, Petraki C, Msaouel P et al (2013) IGF-IEc expression is associated with advanced clinical and pathological stage of prostate cancer. Anticancer Res 33(6):2441–2445
84. Seligson DB, Yu H, Tze S et al (2013) IGFBP-3 nuclear localization predicts human prostate cancer recurrence. Horm Cancer 4(1):12–23
85. Shariat SF, Bergamaschi F, Adler HL et al (2000) Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology 56(3):423–429
86. Soulitzis N, Karyotis I, Delakas D et al (2006) Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 29(2):305–314
87. Stattin P, Soderberg S, Hallmans G et al (2001) Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 86(3):1341–1345
88. Tennant MK, Thrasher JB, Twomey PA et al (1996) Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81(10):3774–3782
89. Thrasher JB, Tennant MK, Twomey PA et al (1996) Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J Urol 155(3):999–1003
90. Tosun Yildirim H, Turk NS (2012) Analysis of imp3 expression in prostate adenocarcinomas. Turk Patoloji Derg 28:128–133
91. Tennant MK, Thrasher JB, Twomey PA et al (1996) Insulin-like growth factor-binding protein-2 and – 3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 81(1):411–420
92. Tricoli JV, Winter DL, Hanlon AL et al (1999) Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 54(1):178–182
93. Tsuchiya N, Narita S, Inoue T et al (2013) Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis. BMC Cancer 13:150
94. Tsuchiya N, Wang L, Suzuki H et al (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24(13):1982–1989
95. Tu SM, Kim J, Wang XM et al (2004) Validating insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 as pertinent therapeutic targets for advanced prostate cancer. J Bone Miner Res 19(9):1585–1585
96. Turney BW, Turner GDH, Brewster SF et al (2011) Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU Int 107(9):1488–1499
97. Woongeol Y, Kwanjin P, Seong Jin J et al (2007) Relation of plasma IGF-1 and IGFBP-3 to the risk of prostate cancer. Eur Urol Suppl 6(2):149–149
98. Yu H, Nicar MR, Shi RH et al (2001) Levels of insulin-like growth factor 1 (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urol 57(3):471–475
99. Zu K, Martin NE, Fiorentino M et al (2013) Protein expression of pten, insulin-like growth factor i receptor (igf-ir), and lethal prostate cancer: A Prospective Study. Cancer Epidemiol Biomark Prev 22(11):1984–1993
100. Lisitskaia KV, Krakhmaleva IN, Shishkin SS (2010) A study of the single nucleotide polymorphism in seven genes (GHR, IGFBP3, IGFR1, IRS1, FMN1, ANXA2, TaGLN) in ethnic Russians and in patients with prostate cancer. Mol Gen Microbiol Virol 25(2):34–37
101. Wolk A, Mantzoros CS, Andersson SO et al (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90(12):911–915
102. Djavan B, Bursa B, Seitz C et al (1999) Insulin-like growth factor 1 (IGF-l), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 54(4):603–606
103. Hill M, Bilek R, Safarik L et al (2000) Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate. Physiol Res 49:S113–S118
104. Koliakos G, Chatzivasiliou D, Dimopoulos T et al (2000) The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. Dis Markers 16(3–4):143–146
105. Ismail H, Pollak M, Behlouli H et al (2002) Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol 168(6):2426–2430
106. Miyata Y, Sakai H, Hayashi T (2003) Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54(2):125–132
107. Scorilas A, Plebani M, Mazza S et al (2003) Serum human glandular kallikrein (hK2) and insulin-like growth factor I (IGF-I) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 54(3):220–229
108. Aksoy Y, Aksoy H, Bakan E et al (2004) Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int 72(1):62–65
109. Nam RK, Trachtenberg J, Jewett MAS et al (2005) Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomark Prev 14(5):1270–1273
110. Trojan L, Bode C, Weiss C et al (2006) IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Eur Urol 49(2):286–292
111. Hong SK, Han BK, Jeong JS et al (2008) Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men. Asian J Androl 10(2):207–213
112. Sciarra A, Gentile V, Monti S et al (2008) Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Urol Int 80(1):68–73
113. Pina FM, Figueiredo G, Lunet N et al (2009) Association between IGF-I and prostatitis, PIN III and prostate cancer diagnosis. Urology 74(4):150
114. Tajtakova M, Pidanicova A, Valansky L et al (2010) Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancer. Neoplasma 57(2):118–122
115. Darago A, Sapota A, Matych J et al (2011) The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer. Clin Chem Lab Med 49(10):1699–1705
116. Khosravi J, Diamandi A, Mistry J et al (2001) Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 86(2):694–699
117. Baffa R, Reiss K, El-Gabry EA et al (2000) Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer. Tech Urol 6(3):236–239
118. Harman SM, Metter EJ, Blackman MR et al (2000) Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85(11):4258–4265
119. Stattin P, Bylund A, Rinaldi S et al (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a Prospective Study. J Natl Cancer Inst 92(23):1910–1917
120. Li L, Yu H, Schumacher F et al (2003) Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 14(8):721–726
121. Woodson K, Tangrea JA, Pollak M et al (2003) Serum insulin-like growth factor 1: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 63(14):3991–3994
122. Janssen JAMJL, Wildhagen MF, Ito K et al (2004) Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 89(9):4391–4396
123. Stattin P, Rinaldi S, Biessy C et al (2004) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a Prospective Study in a population-based nonscreened cohort. J Clin Oncol 22(15):3104–3112
124. Chen C, Lewis SK, Voigt L et al (2005) Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103(1):76–84
125. Meyer F, Galan P, Douville P et al (2005) A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial. Cancer Epidemiol Biomark Prev 14(9):2269–2272
126. Platz EA, Pollak MN, Leitzmann MF et al (2005) Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 16(3):255–262
127. Morris BL, Young T, Van Golen CM: IGF-IR inibition induces MAPK signaling in prostate carcinoma cells. Cancer Res 2011, 71(8 (suppl)):2924 (Abstract)
128. Allen NE, Key TJ, Appleby PN et al (2007) Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev 16(6):1121–1127
129. Li H, Bubley GJ, Balk SP et al (2007) Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate 67(12):1354–1361
130. Weiss JM, Huang WY, Rinaldi S et al (2007) IGF-1 and IGFBP-3: Risk of prostate cancer among men in the prostate, lung, colorectal and ovarian cancer screening trial. Int J Cancer 121(10):2267–2273
131. Mikami K, Ozasa K, Nakao M et al (2009) Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A Nested Case-Control Study in Large Scale Cohort Study in Japan (JACC Study). Asian Pac J Cancer Prev 10:57–61
132. Nimptsch K, Platz EA, Pollak MN et al (2011) Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993–2004. Int J Cancer 128(3):660–667
133. Price AJ, Allen NE, Appleby PN et al (2012) Insulin-like growth factor-i concentration and risk of prostate cancer: results from the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev 21(9):1531–1541
134. Muhlbradt E, Ma J, Severi G et al (2013) Variant NKX3.1 and Serum IGF-1: investigation of interaction in prostate cancer. Genes Cancer 4(11–12):535–545
135. Cohen P, Peehl DM, Stamey TA et al (1993) Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate-cancer patients. J Clin Endocrinol Metab 76(4):1031–1035
136. Mantzoros CS, Tzonou A, Signorello LB et al (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76(9):1115–1118
137. Signorello LB, Brismar K, Bergstrom R et al (1999) Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst 91(22):1965–1967
138. Finne P, Auvinen A, Koistinen H et al (2000) Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85(8):2744–2747
139. Kurek R, Tunn UW, Eckart O et al (2000) The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 85(1):125–129
140. Lacey JV, Hsing AW, Fillmore CM et al (2001) Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomark Prev 10(10):1101–1102
141. Chokkalingam AP, Pollak M, Fillmore CM et al (2001) Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomark Prev 10(5):421–427
142. Li L, Liu J, Anwu T: Significance of determination of serum insulin-like growth factor 1 (IGF- I) in prostate cancer. Tianjin: Tianjin-shi Tixue She 2001.
143. Oliver SE, Gunnell D, Donovan J et al (2004) Screen-detected prostate cancer and the insulin-like growth factor axis: results of a Population-Based Case-Control Study. Int J Cancer 108(6):887–892
144. Marszalek M, Wachter J, Ponholzer A et al (2005) Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. Eur Urol 48(1):34–39
145. Hernandez W, Grenade C, Santos ER et al (2007) IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 28(10):2154–2159
146. Zhao ZG, Liu JM, Li S et al (2007) Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0–10.0 ng/ml. J Surg Oncol 96(1):54–61
147. Borugian MJ, Spinelli JJ, Sun Z et al (2008) Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a Prospective Multiethnic Study. Cancer Epidemiol Biomark Prev 17(1):252–254
148. Kim JH, Park KJ, Bae J-B et al (2009) Plasma insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, and the risk of prostate cancer: a Matched Case-Control Study in a Korean population. Korean J Urol 50(7):645–648
149. Johansson M, McKay JD, Rinaldi S et al (2009) Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate 69(12):1281–1291
150. Gill JK, Wilkens LR, Pollak MN et al (2010) Androgens, growth factors, and risk of prostate cancer: the multiethnic cohort. Prostate 70(8):906–915
151. Kim JH, Lee SW, Jeong SJ et al (2010) The joint association of plasma 1, 25-dihydroxyvitamin D3 and IGFBP-3 levels and VDR FOK1 polymorphism with prostate cancer risk in Korean men. Eur Urol Suppl 9(2):243
152. Park K, Kim JH, Jeon HG et al: Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men. Urology 2010, 75(6)
153. Campa D, Husing A, Chang-Claude J et al (2011) Genetic variability of the fatty acid synthase pathway is not associated with prostate cancer risk in the European prospective investigation on cancer (EPIC). Eur J Cancer 47(3):420–427
154. Neuhouser ML, Platz EA, Till C et al (2013) Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res 6(2):91–99
155. Chan JM, Stampfer MJ, Giovannucci E et al (1998) Plasma insulin-like growth factor I and prostate cancer risk: a prospective study. Science 279(5350):563–566
156. Kaaks R, Lukanova A, Rinaldi S et al (2003) Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 12(4):309–315
157. Stattin P, Stenman UH, Riboli E et al (2001) Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection. J Clin Endocrinol Metab 86(12):5745–5748
158. Chan JM, Stampfer MJ, Ma J et al (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94(14):1099–1106
159. Gu FY, Schumacher FR, Canzian F et al (2010) Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomark Prev 19(11):2877–2887
160. Tsilidis KK, Travis RC, Appleby PN et al (2012) Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the national cancer institute breast and prostate cancer cohort consortium. Am J Epidemiol 175(9):926–935
161. Ho GYF, Melman A, Liu SM et al (2003) Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br J Cancer 88(2):263–269
162. Wang LZ, Habuchi T, Tsuchiya N et al (2003) Insulin-like growth factor-binding protein-3 gene-202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 63(15):4407–4411
163. Li L, Cicek MS, Casey G et al (2004) No association between genetic Polymorphisms in 1GF-1 and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomark Prev 13(3):497–498
164. Friedrichsen DM, Hawley S, Shu J et al (2005) IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate 65(1):44–51
165. Tsuchiya N, Wang LH, Horikawa Y et al (2005) CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol 26(1):225–231
166. Chen C, Freeman R, Voigt LF et al (2006) Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-1, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol Biomark Prev 15(12):2461–2466
167. Hoyo C, Grubber J, Demark-Wahnefried W et al (2007) Grade-specific prostate cancer associations of IGF1(CA)(19) repeats and IGFBP3-202A/C in Blacks and whites. J Natl Med Assoc 99(7):718–722
168. Schumacher FR, Cheng I, Freedman ML et al (2010) A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among. Hum Mol Genet 19(15):3089–3101
169. Neuhausen SL, Slattery ML, Garner CP et al (2005) Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: Strong association of IRS1 G972R variant and cancer risk. Prostate 64(2):168–174
170. Schildkraut JM, Demark-Wahnefried W, Wenham RM et al (2005) IGF1 (CA)(19) repeat and IGFBP3-202A/C genotypes and the risk of prostate cancer in black and white men. Cancer Epidemiol Biomark Prev 14(2):403–408
171. Cheng I, Stram DO, Penney KL et al (2006) Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 98(2):123–134
172. Cheng I, Penney KL, Stram DO et al (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomark Prev 15(10):1993–1997
173. Johansson M, Mckay JD, Wiklund F et al (2007) Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. J Clin Endocrinol Metab 92(12):4820–4826
174. Shariat SF, Lamb DJ, Kattan MW et al (2002) Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and – 3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20(3):833–841
175. Severi G, Morris HA, MacInnis RJ et al (2006) Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomark Prev 15(6):1137–1141
176. Kanety H, Madjar Y, Dagan Y et al (1993) Serum insulin-like growth factor-binding protein-2 (Igfbp-2) is increased and Igfbp-3 is decreased in patients with prostate-cancer - correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77(1):229–233
177. Ho PJ, Baxter RC (1997) Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 46(3):333–342
178. Cutting CWM, Hunt C, Nisbet JA et al (1999) Serum insulin-like growth factor-1 is not a useful masker of prostate cancer. Bju Int 83(9):996–999
179. Perk H, Serel TA, Delibas N et al (2001) Prostatic fluid-free insulin-like growth factor-1 in relation to prostate cancer. Bju Int 88(9):946–949
180. Peng L, Tang S, Xie J (2002) Quantitative analysis of IGF-1 and its application in the diagnosis of prostate cancer. Hua-Hsi i Ko Ta Hsueh Hsueh Pao [Journal of West China University of Medical Sciences] 33:137–139
181. Trapeznikova MF, Shibaeva AN, Ianshin A (2004) Vascular endothelium growth factor and insulin-like growth factors in prostatic cancer. Urologiya 1:17–21
182. Lopez JB, Sahabudin RM, Chin LP (2004) Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer? Int J Biol Markers 19(2):164–167
183. Kehinde EO, Akanji AO, Mojiminiyi OA et al (2005) Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. Prostate Cancer Prostatic Dis 8(1):84–90
184. Iltaf M, Jagdesh, Panjwani JP et al (2013) Trait marker IGF1 is more diagnostic than PSA in Ca prostate, study at local population of Karachi. Pak J Med Health Sci 7:626–629
185. Sarma AV, Dunn RL, Lange LA et al (2008) Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The flint men’s health study. Prostate 68(3):296–305
186. Silha JV, Sheppard PC, Mishra S et al (2006) Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147(5):2112–2121
187. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ et al (2008) Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 68(9):3495–3504
188. Anzo M, Cobb LJ, Hwang DL et al (2008) Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res 68(9):3342–3349
189. Mehta HH, Gao QL, Galet C et al (2011) IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res 71(15):5154–5163
190. Goya M, Miyamoto S, Nagai K et al (2004) Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64(17):6252–6258
191. Wu JD, Odman A, Higgins LM et al (2005) In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11(8):3065–3074
192. Ingermann AR, Yang YF, Han JF et al (2010) Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem 285(39):30233–30246
193. Kimura T, Kuwata T, Ashimine S et al (2010) Targeting of bone-derived insulin-like growth factor-ii by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 16(1):121–129
194. DiGiovanni J, Kiguchi K, Frijhoff A et al (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 97(7):3455–3460
195. Fu VX, Dobosy JR, Dosetelle JA et al (2008) Aging-related loss of insulin-like growth factor-2 (Igf2) imprinting in the prostate. J Urol 179(4):394–394
196. Martin RM, Holly JMP, Gunnell D (2011) Milk and linear growth: programming of the IGF-I axis and implication for health in adulthood. Milk Milk Prod Hum Nutr 67:79–97
197. Tsilidis KK, Papatheodorou SI, Evangelou E et al (2012) Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk. J Natl Cancer Inst 104(24):1867–1878
198. Ramos-Levi AM, Marazuela M, Paniagua A et al (2015) Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments. Eur J Endocrinol 172(2):115–122
199. Bonilla C, Lewis SJ, Rowlands MA et al (2016) Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: genetic variants as instruments for circulating levels. Int J Cancer 139(7):1520–1533